IVis Technologies History & Mission. LIGI Tecnologie Medicali was founded in 1993 by Giuseppe D’Ippolito and his wife Liliana Guarini, who was already

iVis TechnologiesHistory & Mission

LIGI Tecnologie Medicali was founded in 1993 by Giuseppe D’Ippolito and his wife Liliana Guarini, who was already trading in the ophthalmic market since 1986, with her own firm, selling disposable and consumables to public hospitals.

Giuseppe D’Ippolito is an engineer with a specific passion for research and development in the medical field.

The main reason to found LIGI Tecnologie Medicali was an idea by Giuseppe D’Ippolito, later on patented by LIGI Tecnologie Medicali, to drive the spot laser onto the cornea to plan and execute an ideal surgical profile customized to patients’ needs to optimize vision and minimize the treatment invasiveness.

As a consequence, LIGI Tecnologie Medicali started as a software house, to develop and market software for corneal refractive and therapeutic customized ablation.

Lig

i Per

iod

fro

m 1

993

to 2

007 Company History 1993 – 1995

Reaching your destination requires knowing your starting point!

In 1995, LIGI Tecnologie Medicali signed a first agreement with Lasersight Inc., Orlando - Florida - USA, the manufacturer of the LaserScan, the first flying-spot excimer laser introduced in the market, to develop a software for custom ablation. This allowed LIGI Tecnologie Medicali to drive their excimer laser to execute refractive and therapeutic custom profiles according to LIGI Tecnologie Medicali strategy.

In the same year LIGI, Tecnologie Medicali entered a second agreement with Orbtek Inc., Salt Lake City – Utah – USA, manufacturer of the Orbscan, the first tomographer detecting the true corneal shape, to extract true corneal elevation data in order to plan refractive and therapeutic customized profiles according to LIGI Tecnologie Medicali strategy.

Lig

i Per

iod

fro

m 1

993

to 2



In 1996 LIGI Tecnologie Medicali started the development of the CIPTA® software to plan refractive and therapeutic customized profiles.

LIGI Tecnologie Medicali entered the laser vision correction market signing a distribution agreement for Italy with both LaserSight Inc. and Orbtek Inc.

Software validation and clinical trials on the CIPTA® software were completed by 1997.

In the same year, LIGI began installing in Italy platforms for customized refractive and therapeutic surgery composed of the Orbscan tomographer, produced by Orbtek Inc., to detect the corneal shape, the CIPTA® software to plan the ideal custom refractive and therapeutic ablation profiles and the Laserscan excimer laser produced by LaserSight Inc. to deliver the custom profiles.

Lig

i Per

iod

fro

m 1

993

to 2



In 1999, LIGI Tecnologie Medicali patented the CIPTA® platform to customize refractive surgery.

LIGI Tecnologie Medicali granted LaserSight Inc. a worldwide non-exclusive license to market the CIPTA® software together with the Laserscan excimer.

In the same year, LIGI Tecnologie Medicali introduced in the market the CLAT® software to customize corneal lamellar transplantation.

In the following year, LIGI Tecnologie Medicali patented the CLAT® software to customize corneal lamellar transplantation.

Lig

i Per

iod

fro

m 1

993

to 2



In 2002 LIGI Tecnologie Medicali decided to start an extensive R&D program that led to the iVis Suite™ platform.

Differently from all competitors in the market, the R&D program of the iVis Suite™ was centered around the CIPTA® and CLAT® software to customize refractive and therapeutic surgery.

The primary objective of the iVis Suite™ R&D was creating superior devices that would allow to exploit fully the surgical capabilities of CIPTA® and CLAT® and treating a wide array of cornel pathologies, untreatable with competitive systems.

Lig

i Per

iod

fro

m 1

993

to 2



As a consequence all the hardware devices of the iVis Suite™ platform were conceived as an unique and coherent ensemble conceived to grant the surgeon the ability to plan and to execute cTen™ (custom Trans epithelial no-touch) surgeries, to optimize patient quality of vision, to minimize treatment invasiveness and to avoid intra-operative risks.

System validation and clinical trials on the iVis Suite™ were completed by 2007.

The iVis Suite™ was ready to be launched on the market in 2007.

Lig

i Per

iod

fro

m 1

993

to 2



iVis Technologies was incorporated, as a spinoff of LIGI Tecnologie Medicali, to address the international marketing activities for the iVis Suite™.

iVis Technologies marketing efforts focused on those surgeons showing great interest for innovating technologies in customized corneal no-touch surgery.

The iVis Suite™ was installed worldwide, since 2008, in 9 countries (Italy, Norway, Switzerland, Australia, Austria, Slovenia, Spain, Canada and Kenya).

All installations of the iVis Suite™ are implemented and directly managed by the Italian Headquarter of iVis Technologies.

iVis

Per

iod

fro

m 2

007

to 2



The iVis Suite™ received, in 2008, an award by the Ministry of Research and Education as one of the top 10 R&D projects in Italy.

iVis Technologies received, in 2009, the OSEO Certification as “Innovative Enterprise” from the Ministry of Industry and Innovation of France.

iVis Technologies received, in 2013, the prestigious Technology Innovation Award from SOI (Italian Ophthalmology Society).

AwardsReaching your destination requires knowing your starting point!

iVis

Per

iod

fro

m 2

007

to 2

014

The main focus of iVis Technologies is leading the high-end sector of the corneal refractive and therapeutic market by designing, engineering, producing and marketing the iVis SuiteTM platform.

The iVis SuiteTM in an unique ensemble of hardware and software devices, wirelessly interconnected, fully automated, with a closed-loop web-based control, conceived as “One Body”. The iVis Suite™ grants surgeons the possibility to plan and to execute cTenTM (Custom Trans epithelial no-touch) surgeries, optimizing patient quality of vision, minimizing treatment invasiveness and avoiding intra-operative risks.

Mis

sio

nNo-Touch Corneal SurgeryReaching your destination requires knowing your starting point!

Mis

sio

nNo-Touch Corneal SurgeryReaching your destination requires knowing your starting point!

The IVIS Suite grants the surgeon to plan and to execute cTen™ (custom Trans-epithelial no-touch) surgeries, to optimize patient quality of vision, to minimize treatment invasiveness and to avoid intraoperative risks to treat:

• Refractive diseases for far vision; • Refractive diseases for near and far vision;• Complex therapeutic corneal diseases;• Complex therapeutic corneal diseases, requiring crosslinking corneal

stabilization.

The full iVis Suite™, hardware and software, was conceived, designed and produced internally. Competitors, on the other hand, starting from an excimer laser, subsequently went onto the market to source additional devices (e.g. Topographers and/or Wavefront analysers) to couple to their lasers;

The iVis Suite™ devices were conceived and designed to exploit fully the capabilities of CIPTA® and CLAT®. The iVis Suite™ R&D project was therefore software-centric. Due to this innovative R&D approach, all devices lead by performance.

iVerify™ generates the follow up analysis on Precisio™. The iVerify™ follow-up of the iVis Suite is an unique functionality developed by iVis Technologies to control, differently from Competitors, the process reliability from pre-op examination till post-op verification.

Str

eng

th &

Wea

knes

siVis Technologies and Competitive SystemsReaching your destination requires knowing your starting point!

Technological Leadership: the unique refractive and therapeutic surgical capabilities of the iVis Suite™ are unmatched either for performance, being it the only platform entirely conceived within one company, as for reliability, thanks to the unique web integrated follow–up analysis of the surgical outcomes.

Vision and Creativity: Since the beginning of its activities, iVis demonstrated unmatched vision and creativity in corneal surgery, still strongly present in the R&D programs currently under development.

Speed: iVis Technologies executed its R&D program with exceptional speed, the extensive iVis Suite™ R&D project was completed in only a few years. This time is shorter than the average time competing multinational companies take to complete much less extensive R&D projects.

Full array of core competencies: iVis Technologies uniquely possess all core competencies (software, electronic, mechanical, etc.) that lead to the development of the iVis Suite™ platform.


The iVis Suite™, due to this innovative R&D approach, is therefore composed of hardware and software devices that are winning over competitors and leading the industry either in terms of performance as for reliability.

The iVis Suite™ has the capability to perform not only refractive surgery, but thanks to its customized patented approach, to treat an array of therapeutic pathologies. Thus providing the market a solution to a wide range of corneal pathologies that are currently untreatable with competing systems.

Str

eng

th &

Wea

knes

siVis Technologies LeadershipReaching your destination requires knowing your starting point!

iVis Technologies

Innovative Solutions for Custom Refractive

and Custom TherapeuticSurgeries

Documents

IVis Technologies History & Mission. LIGI Tecnologie Medicali was founded in 1993 by Giuseppe D’Ippolito and his wife Liliana Guarini, who was already